The additional funding from the US Department of Defense is a strong endorsement of MediWound's NexoBrid and its potential in military applications. This non-dilutive funding enhances the company's financial position without diluting existing shareholders' equity. The news is likely to be viewed positively by investors, as it not only validates the product's potential but also provides financial resources to continue its development. This could lead to a short-term positive impact on MediWound's stock price.